Xspray Pharma’s Nomination Committee for the Annual General Meeting 2023
Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) publishes the Nomination Committee’s composition for the Annual General Meeting in 2023. The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting on 19 May 2022, consists of: Thomas Eldered, appointed by Flerie Invest AB Johan Gyllenswärd, appointed by Ribbskottet AB […]
Read moreXspray Pharma has carried out a directed share issue raising proceeds of MSEK 100
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR OTHER MEASURES. Xspray Pharma AB (publ) (“Xspray” or the “Company”) has, based on […]
Read moreInterim Report Second Quarter 2022
A vision to improve patients’ lives Second quarter 2022 (April–June), Group· Net sales amounted to SEK 0 thousand (0)· Loss before tax amounted to SEK -28,865 thousand (-16,952)· Earnings per share before dilution amounted to SEK -1.40 (-0.89)· Cash flow from operating activities amounted to SEK -24,472 thousand (-12,831)· Cash flow from investing activities amounted to SEK -29,197 […]
Read moreDasynoc granted Orphan Drug Designation in the US for the treatment of chronic myeloid leukemia
Xspray Pharma (Nasdaq Stockholm: Xspray) today announced that the US Food and Drug Administration (FDA) has granted Dasynoc Orphan Drug Designation (ODD) in the US for the treatment of chronic myeloid leukemia (CML). The FDA decision to grant the designation is based on the plausible hypothesis that Dasynoc may be clinically superior to the same […]
Read moreXspray Pharma appoints Thomas Walz as Chief Medical Officer
Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) announces today that the company has appointed Thomas Walz to the newly established position Chief Medical Officer (CMO). Thomas joins Xspray Pharma from a senior role at GSK and will take up the new position in September 2022. “As Xspray Pharma takes steps towards a sharp commercialization phase […]
Read moreXspray Pharma’s long-term incentive program LTI 2022 fully subscribed
Xspray Pharma AB (publ) today announces the outcome of the subscription of options in the incentive program approved at the Annual General Meeting on May 19, 2022. The long-term incentive program 2022 (LTI 2022) in the form of warrants and employee stock options was fully subscribed, in total 421,875 options will be issued. All members […]
Read moreBulletin from the 2022 Annual General Meeting of Xspray Pharma AB (publ)
The following resolutions were passed at the annual general meeting (the “AGM”) of Xspray Pharma AB (publ) (“Xspray”) on 19 May 2022. Adoption of income statement and balance sheet for the financial year 2021 and discharge from liabilityThe AGM resolved to adopt the income statement and the consolidated income statement for the financial year 2021 […]
Read moreXspray Pharma – Capital Markets Day Invitation
Xspray Pharma hereby invites investors, analysts, media representatives and other stakeholders to a Capital Markets Day, Tuesday May 24, 2022 at 10.00-12.00 CET, followed by lunch, at Hallvarsson & Halvarson, Sveavägen 20, Stockholm. The Capital Markets Day will be webcast between 10.00-12.00 CET. After the Capital Markets Day an on-demand replay will be available on […]
Read moreAn eventful quarter sets the agenda for an intense 2022
First Quarter 2022 (January 1 – March 31), Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -18,934 thousand (-13,912) Earnings per share before dilution amounted to SEK -0.92 (-0.73) Cash flow from operating activities amounted to SEK -27,613 thousand (-11,971) Cash flow from investing activities amounted to SEK […]
Read moreThe Nomination Committee’s proposal for the Board of Directors of Xspray Pharma AB
The Nomination Committee proposes Robert Molander as a new member of the Board of Directors at the Annual General Meeting. The Nomination Committee proposes that members of the Board of Directors Anders Ekblom (Chairman since 2021), Anders Bladh (member since 2021), Maris Hartmanis (member since 2015), Torbjörn Koivisto (member since 2017), Christine Lind (member since […]
Read more